Literature DB >> 15542740

Involvement of glial glutamate transporters in morphine dependence.

Takayuki Nakagawa1, Masamichi Satoh.   

Abstract

There are several lines of evidence implying the involvement of the central glutamatergic system in morphine dependence. Extracellular glutamate released from nerve terminals is counterbalanced by glutamate transporters in neurons (EAAC1 and EAAT4) and glial cells (GLT-1 and GLAST), thereby modulating the glutamatergic system and protecting neurons from an excitotoxic action of glutamate. Here we show that a glial glutamate transporter GLT-1 could be involved in physical and psychological morphine dependence. By Northern blot analysis, the expression of glial glutamate transporter GLT-1, but not GLAST, mRNA was decreased in the striatum/nucleus accumbens (NAc) and thalamus of morphine-dependent rats. Subcutaneous administration of a glutamate transporter activator suppressed the development of physical morphine dependence and morphine-induced conditioned place preference. Intracerebroventricular administration of a glutamate transporter inhibitor to morphine-dependent rats facilitated the expression of naloxone-precipitated morphine withdrawal-induced somatic signs and conditioned place aversion. Furthermore, gene transfer techniques using recombinant adenoviruses revealed that GLT-1 in the locus coeruleus and NAc shell plays inhibitory roles in physical and psychological morphine dependence, respectively. These findings may provide evidence that a glial glutamate transporter GLT-1 could be a new target for preventing physical and psychological morphine dependence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542740     DOI: 10.1196/annals.1307.047

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  18 in total

Review 1.  Glutamate transporter 1: target for the treatment of alcohol dependence.

Authors:  P S S Rao; Y Sari
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 2.  Control of ACTH secretion by excitatory amino acids: functional significance and clinical implications.

Authors:  Daniela Jezova
Journal:  Endocrine       Date:  2005-12       Impact factor: 3.633

Review 3.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

4.  beta-Lactam antibiotic inhibits development of morphine physical dependence in rats.

Authors:  Scott M Rawls; David A Baron; Jae Kim
Journal:  Behav Pharmacol       Date:  2010-03       Impact factor: 2.293

Review 5.  The Opioid-Addicted Tetrapartite Synapse.

Authors:  Anna Kruyer; Vivian C Chioma; Peter W Kalivas
Journal:  Biol Psychiatry       Date:  2019-06-13       Impact factor: 13.382

6.  Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia.

Authors:  Mark R Hutchinson; Alexis L Northcutt; Lindsey W Chao; Jeffrey J Kearney; Yingning Zhang; Debra L Berkelhammer; Lisa C Loram; Robert R Rozeske; Sondra T Bland; Steven F Maier; Todd T Gleeson; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2008-07-31       Impact factor: 7.217

7.  The beta-lactam antibiotic, ceftriaxone, attenuates morphine-evoked hyperthermia in rats.

Authors:  S M Rawls; R Tallarida; W Robinson; M Amin
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

8.  Extracellular signal-regulated kinase activation in the amygdala mediates elevated plus maze behavior during opioid withdrawal.

Authors:  Rebecca S Hofford; Stephen R Hodgson; Kris W Roberts; Camron D Bryant; Christopher J Evans; Shoshana Eitan
Journal:  Behav Pharmacol       Date:  2009-10       Impact factor: 2.293

9.  Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast).

Authors:  Mark R Hutchinson; Susannah S Lewis; Benjamen D Coats; David A Skyba; Nicole Y Crysdale; Debra L Berkelhammer; Anita Brzeski; Alexis Northcutt; Christine M Vietz; Charles M Judd; Steven F Maier; Linda R Watkins; Kirk W Johnson
Journal:  Brain Behav Immun       Date:  2008-10-04       Impact factor: 7.217

Review 10.  Why is neuroimmunopharmacology crucial for the future of addiction research?

Authors:  Mark R Hutchinson; Linda R Watkins
Journal:  Neuropharmacology       Date:  2013-06-11       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.